001     284031
005     20260119111627.0
024 7 _ |a 10.1212/WNL.0000000000214401
|2 doi
024 7 _ |a pmid:41538773
|2 pmid
024 7 _ |a 0028-3878
|2 ISSN
024 7 _ |a 1526-632X
|2 ISSN
037 _ _ |a DZNE-2026-00074
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Lopriore, Piervito
|0 0000-0002-9789-3129
|b 0
245 _ _ |a Clinical and Genotypic Spectrum of Twinkle-Related Disorders: Insights From a Multinational Cohort Study.
260 _ _ |a Philadelphia, Pa.
|c 2026
|b Wolters Kluwer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1768817689_6722
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Twinkle, encoded by the TWNK gene, is a mitochondrial DNA helicase that unwinds the double helix of DNA during replication, playing a pivotal role in mitochondrial function. Twinkle-related disorders encompass a variety of genetic disorders characterized by mitochondrial dysfunction. Although several phenotypes have been described, the full clinical and molecular spectrum remains poorly defined. The aim of this study was to characterize the phenotypic and genotypic variability among multinational patients diagnosed with Twinkle-related disorders.A retrospective cohort study was conducted in patients with Twinkle-related disorders at several specialized centers in Italy, France, Germany, Spain, Denmark, Hungary, and the United States, establishing the Twinkle-Related Disorders International Consortium for Trial Readiness (TReDIC). Data were collected from medical records, including clinical features, age at onset, disease progression, and results from genetic testing. Phenotypic categories included infantile-onset cerebellar ataxia, parkinsonism, primary mitochondrial myopathy (PMM), multisystem involvement, asymptomatic carriers, undetermined phenotypes, and other phenotypes. All patients' diagnoses were confirmed by genetic analysis, and their genetic variants were noted. Outcomes included prevalence of phenotypes, symptom chronology, and mutational patterns.The study included a total of 189 patients (116 female), with a mean age at symptom onset of 40.3 years. At the time of analysis, 70.4% were alive. PMM was the predominant syndrome (85.2%), and most common features were progressive external ophthalmoplegia (84.7%) and skeletal myopathy (55.6%), followed by hearing loss (17.5%) and psychiatric symptoms (15.3%). Most patients (76.8%) presented with neuromuscular symptoms, with fewer showing CNS (19.6%) or multiorgan (3.6%) features at onset; by more than 8 years from onset, these proportions shifted to 54.4%, 23.3%, and 23.3%, respectively. A total of 73 TWNK variants (16 novel) were found, mostly missense, clustered in functionally critical regions.This large multinational cohort analysis advances our understanding of Twinkle-related disorders by identifying mutational hotspots with clinical relevance and illustrating the broad phenotypic spectrum and progression patterns. In the context of such rare diseases, the formation of international collaborations, such as TReDIC, can enhance our understanding and support the design of upcoming clinical trials.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a TWNK protein, human
|0 EC 3.6.4.12
|2 NLM Chemicals
650 _ 7 |a Mitochondrial Proteins
|2 NLM Chemicals
650 _ 7 |a DNA Helicases
|0 EC 3.6.4.-
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Child
|2 MeSH
650 _ 2 |a Phenotype
|2 MeSH
650 _ 2 |a Genotype
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
650 _ 2 |a Mitochondrial Diseases: genetics
|2 MeSH
650 _ 2 |a Mitochondrial Diseases: physiopathology
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Mitochondrial Proteins: genetics
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Child, Preschool
|2 MeSH
650 _ 2 |a Mutation
|2 MeSH
650 _ 2 |a Age of Onset
|2 MeSH
650 _ 2 |a Mitochondrial Myopathies: genetics
|2 MeSH
650 _ 2 |a DNA Helicases
|2 MeSH
700 1 _ |a Ünlütürk, Zeynep
|0 0000-0003-3236-6712
|b 1
700 1 _ |a Klopstock, Thomas
|0 P:(DE-2719)2810704
|b 2
700 1 _ |a Karaa, Amel
|0 0000-0001-5781-9824
|b 3
700 1 _ |a Rouzier, Cecile
|0 0000-0002-2969-1904
|b 4
700 1 _ |a Domínguez-González, Cristina
|0 0000-0001-5151-988X
|b 5
700 1 _ |a Lamperti, Costanza
|0 0000-0002-2280-2253
|b 6
700 1 _ |a Mancuso, Michelangelo
|0 0000-0003-2738-8562
|b 7
700 1 _ |a Readiness, Twinkle-Related Disorders International Consortium for Trial
|b 8
|e Collaboration Author
700 1 _ |a Cecchi, Giulia
|b 9
700 1 _ |a Montano, Vincenzo
|0 0000-0002-7548-7699
|b 10
700 1 _ |a Siciliano, Gabriele
|0 0000-0002-6142-2384
|b 11
700 1 _ |a Nicoletta, Valeria
|0 0009-0006-3630-3726
|b 12
700 1 _ |a Maioli, Mariantonietta
|b 13
700 1 _ |a Primiano, Guido
|0 0000-0001-7616-7008
|b 14
700 1 _ |a Servidei, Serenella
|0 0000-0001-8478-2799
|b 15
700 1 _ |a La Morgia, Chiara
|0 0000-0002-4639-8929
|b 16
700 1 _ |a Carelli, Valerio
|0 0000-0003-4923-6404
|b 17
700 1 _ |a Valentino, Maria Lucia
|0 0000-0001-5323-0115
|b 18
700 1 _ |a Caporali, Leonardo
|0 0000-0002-0666-4380
|b 19
700 1 _ |a Arena, Ignazio Giuseppe
|b 20
700 1 _ |a Musumeci, Olimpia
|0 0000-0002-9208-1527
|b 21
700 1 _ |a Lopergolo, Diego
|0 0000-0003-2256-0482
|b 22
700 1 _ |a Malandrini, Alessandro
|0 0000-0003-1034-0845
|b 23
700 1 _ |a Gallus, Gian Nicola
|0 0000-0001-5801-223X
|b 24
700 1 _ |a Filosto, Massimiliano
|0 0000-0002-2852-7512
|b 25
700 1 _ |a Bello, Luca
|0 0000-0002-3075-6525
|b 26
700 1 _ |a Pegoraro, Elena
|0 0000-0002-7740-4156
|b 27
700 1 _ |a Comi, Giacomo Pietro
|0 0000-0002-1383-5248
|b 28
700 1 _ |a Magri, Francesca
|0 0000-0001-8974-9453
|b 29
700 1 _ |a Ronchi, Dario
|0 0000-0002-6093-9816
|b 30
700 1 _ |a Di Fonzo, Alessio
|0 0000-0001-6478-026X
|b 31
700 1 _ |a Percetti, Marco
|b 32
700 1 _ |a Azzimonti, Matteo
|0 0009-0008-7333-6046
|b 33
700 1 _ |a Büchner, Boriana
|0 0000-0002-1241-3684
|b 34
700 1 _ |a Prokisch, Holger
|0 0000-0003-2379-6286
|b 35
700 1 _ |a Bermejo-Guerrero, Laura
|0 0000-0002-8349-715X
|b 36
700 1 _ |a Procaccio, Vincent
|b 37
700 1 _ |a Gaignard, Pauline
|0 0000-0002-9520-2013
|b 38
700 1 _ |a Echaniz-Laguna, Andoni
|0 0000-0003-1012-9783
|b 39
700 1 _ |a Schiff, Manuel
|0 0000-0001-8272-232X
|b 40
700 1 _ |a Rötig, Agnès
|0 0000-0003-0589-0703
|b 41
700 1 _ |a Toutain, Annick
|b 42
700 1 _ |a Paquis-Flucklinger, Véronique
|b 43
700 1 _ |a Morel, Godelieve
|b 44
700 1 _ |a Robin, Stéphanie
|b 45
700 1 _ |a Nadaj-Pakleza, Aleksandra
|0 0009-0002-7212-3918
|b 46
700 1 _ |a Chanson, Jean-Baptiste
|b 47
700 1 _ |a Chaussenot, Annabelle
|b 48
700 1 _ |a Ait-El-Mkadem Saadi, Samira
|b 49
700 1 _ |a Trimouille, Aurélien
|b 50
700 1 _ |a Tranchant, Christine
|0 0000-0002-2895-1292
|b 51
700 1 _ |a Salort-Campana, Emmanuelle
|0 0000-0002-1846-3017
|b 52
700 1 _ |a Bieth, Eric
|b 53
700 1 _ |a Sacconi, Sabrina
|0 0000-0002-0246-1455
|b 54
700 1 _ |a Duval, Fanny
|b 55
700 1 _ |a Restrepo Vera, Juan Luis
|b 56
700 1 _ |a Molnar, Maria Judit
|b 57
700 1 _ |a Vissing, John
|0 0000-0001-6144-8544
|b 58
700 1 _ |a Haas, Richard
|0 0009-0001-4728-2792
|b 59
700 1 _ |a Larson, Austin
|0 0000-0002-2079-6929
|b 60
700 1 _ |a Enns, Gregory M
|b 61
700 1 _ |a Parikh, Sumit
|0 0000-0003-3712-8959
|b 62
700 1 _ |a Goldstein, Amy
|0 0000-0001-6593-5905
|b 63
700 1 _ |a Hirano, Michio
|0 0000-0002-7070-7402
|b 64
773 _ _ |a 10.1212/WNL.0000000000214401
|g Vol. 106, no. 3, p. e214401
|0 PERI:(DE-600)1491874-2
|n 3
|p e214401
|t Neurology
|v 106
|y 2026
|x 0028-3878
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810704
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROLOGY : 2022
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROLOGY : 2022
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21